Loading...
•
Sep 30, 2020
Repligen Q3 2020 Earnings Report
Reported record quarterly revenue with strong margin expansion.
Key Takeaways
Repligen reported a strong third quarter in 2020, achieving a record quarterly revenue of $94.1 million, driven by a 35% year-over-year growth and a 31% organic growth. COVID programs accounted for approximately 14% of revenue during the quarter, contributing to approximately 55% of revenue growth. The company also updated its full-year 2020 financial guidance, raising revenue expectations to $348-$352 million.
Repligen reported record quarterly revenue of $94.1 million, with a 35% year-over-year increase and 31% organic growth.
Gross margin (GAAP) was 57.9%, an increase of 3.1 points, and adjusted gross margin (non-GAAP) was 58.0%, an increase of 1.9 points compared to third quarter of 2019.
Operating margin (GAAP) was 22.3%, an increase of 10.8 points, and adjusted operating margin (non-GAAP) was 28.6%, an increase of 6.8 points compared to the third quarter of 2019.
The company raised revenue guidance to $348-$352 million and overall revenue growth to 29%-30% for full year 2020.
Forward Guidance
Repligen updated its financial guidance for the fiscal year 2020, projecting total revenue in the range of $348-$352 million and adjusted fully diluted EPS in the range of $1.41-$1.45.
Positive Outlook
- Total revenue is projected to be in the range of $348-$352 million, an increase from our previous guidance of $332-$340 million.
- Overall revenue growth of 29%-30%, with organic revenue growth in the range of 23%-24%.
- Gross margin is expected to be in the range of 57.5%-58.0% on both a GAAP and non-GAAP basis, compared to our previous guidance of 56.5%-57%.
- Income from operations is expected to be in the range of $66-$68 million on a GAAP basis, an increase from our previous guidance of $59-$62 million.
- Adjusted income from operations (non-GAAP) is expected to be in the range of $91-$93 million, an increase from our previous guidance of $81-$84 million.
Challenges Ahead
- The guidance does not include the impact of our proposed acquisition of ARTeSYN Biosolutions, which is expected to close during the fourth quarter of 2020.
- The guidance also excludes the impact of potential additional acquisitions and future fluctuations in foreign currency exchange rates.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...